Cuvitru

Quick orientation

Cuvitru (immune globulin subcutaneous, human, 20% solution) is a ready-to-use subcutaneous immunoglobulin (SCIG) developed by Takeda (originally Baxalta/Shire). The US Food and Drug Administration approved Cuvitru in September 2016 as replacement therapy for primary humoral immunodeficiency (PI) in adult and paediatric patients aged two years and older, including conditions such as common variable immunodeficiency, X-linked agammaglobulinaemia, congenital agammaglobulinaemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Cuvitru is administered subcutaneously, typically once weekly or every two weeks after individualised dose titration, and can be self-administered at home following training. Treatment is supervised by an allergist-immunologist experienced in immunoglobulin replacement therapy.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Cuvitru

1. Patient or treating physician submits an intake at the patient portal.
2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific named-patient documentation is prepared.
5. Cuvitru is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Cuvitru in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Start a request for Cuvitru

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp